AzTrials
AzTrials

B Cell LymphomaPhase 1NCT04088864

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

A Phase 1 study testing Fludarabine, Cyclophosphamide and Autologous CD22 CAR T in people with B Cell Lymphoma and Acute Lymphoblastic Leukemia, Pediatric, run by Kara Lynn Davis at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from pediatric and young adult subjects with relapsed/refractory B-cell malignancies (leukemia and lymphoma). Read more about this study

Who is it for?
Ages 1 year to 30 years
What is being tested?
Fludarabine, Cyclophosphamide and Autologous CD22 CAR T
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited States
Study dates
10 Jan 2020to 13 Jan 2022
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year to 30 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Disease Status Disease Status of ALL
  • Must have chemotherapy refractory disease defined as progression or stable disease after two lines of therapies, or
  • Relapsed disease after achieving CR.
  • Subjects with persistent or relapsed minimal residual disease (MRD) (by flow cytometry, PCR, fluorescence in situ hybridization (FISH), or next generation sequencing (NGS) require verification of MRD on two occasions at least 2 weeks apart.
  • Subjects with Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ALL) subjects are eligible if they progressed, had stable disease or relapsed after two lines of therapy, including tyrosine kinase inhibitors (TKIs).
  • Subjects with recurrence of isolated central nervous system CNS) relapse after achieving complete remission (CR).
Show all 49Show fewer
  • Disease Status of lymphoma
  • Histologically confirmed aggressive B cell NHL including the following types defined by WHO 2008:
  • DLBCL not otherwise specified; T cell/histiocyte rich large B cell lymphoma; DLBCL associated with chronic inflammation; Epstein Barr virus (EBV)+ DLBCL of the elderly; OR primary mediastinal (thymic) large B cell lymphoma transformation of follicular lymphoma, marginal zone lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma to DLBCL will also be included
  • Subjects with DLBCL must have progressed, had SD, or recurred after initial treatment regimens that include an anthracycline and an anti CD20 monoclonal antibody. Subjects with transformed Follicular lymphoma(FL), marginal zone B-cell lymphoma (MZL), or chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) must have progressed, had SD, or recurred with transformed disease after initial treatment for DLBCL. Subjects who relapse ≥12 months after therapy should have progressed after autologous transplant or been ineligible for autologous transplant.
  • Measureable Disease
  • Subjects with ALL must have evaluable or measurable disease.
  • Subjects with lymphoma: Must have evaluable or measurable disease according to the revisedInternational Working. Group( IWG) Response Criteria for Malignant Lymphoma. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.
  • CD22 expression
  • Subjects with ALL: CD22 positive expression on malignant cells is required and must be detected by immunohistochemistry or by flow cytometry. The choice of whether to use flow cytometry or immunohistochemistry will be determined by what is the most easily available tissue sample in each subject.
  • CD22 expression must be demonstrated subsequent to any anti-CD22 targeted therapy (e.g. Moxetumomab pasudotox or inotuzumab ozogamicin) in subjects with ALL
  • Subjects with lymphoma: must have archival tissue available for analysis of CD22 expression, or must be willing to undergo a biopsy of easily accessible disease.
  • Prior Bone Marrow-Stem Cell Transplant Subjects who have undergone autologous stem cell transplant (SCT) with disease progression or relapse following SCT are eligible. Subjects who have undergone allogeneic SCT will be eligible if, in addition to meeting other eligibility criteria, they are at least 100 days post transplant, they have no evidence of Graft versus host disease (GVHD) and have been without immunosuppressive agents for at least 30 days.
  • Prior Therapy Wash-out
  • At least 2 weeks or 5 half lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires 5 half lives.
  • Subjects with ALL may not have receive inotuzumab ozogamicin therapy within the past 4 months.
  • Exceptions:
  • There is no time restriction with regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such;
  • Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least 2 weeks prior to starting apheresis;
  • Subjects who are on standard ALL maintenance type chemotherapy (vincristine, 6- mercaptopurine or oral methotrexate) may be enrolled provided that chemotherapy is discontinued at least 1 week or 5 half-lives, whichever is shorter,prior to apheresis.
  • Subjects receiving steroid therapy at physiologic replacement doses (≤ 5 mg/day of prednisone or equivalent doses of other corticosteroids) only are allowed provided there has been no increase in dose for at least 2 weeks prior to starting apheresis;
  • For radiation therapy: Radiation therapy must have been completed at least 3 weeks prior to enrollment, with the exception that there is no time restriction if the volume of bone marrow treated is less than 10% and also the subject has measurable/evaluable disease outside the radiation port or the site of radiation has documented progression.
  • Prior CAR Therapy Subjects who have undergone prior CAR therapy will be eligible if at least 30 days has elapsed prior to apheresis.
  • Toxicities from Prior Therapy Toxicities due to prior therapy must be stable (except for clinically non significant toxicities such as alopecia)
  • Age greater than or equal to 1 year and ≤ 30 years of age at time of enrollment. First 3 subjects treated at the dose level must be at least 16 years old (enrolled on either pediatric or adult protocol).
  • Performance Status:
  • Subjects > 10 years of age: Karnofsky ≥ 70% OR Eastern cooperative oncology group (ECOG) performance status of 0 or 1; Subjects ≤ 10 years of age: Lansky scale ≥ 70%
  • Normal Organ and Marrow Function (supportive care is allowed per institutional standards, i.e. filgrastim, transfusion)
  • Absolute neutrophil count (ANC) ≥ 750/uL*
  • Platelet count ≥ 50,000/uL*
  • Absolute lymphocyte count ≥ 150/uL*
  • Adequate renal, hepatic, pulmonary and cardiac function defined as:
  • Creatinine within institutional norms for age (i.e. ≤ 2 mg/dL in adults or according to table below in children <18 years) OR creatinine clearance (as estimated by Cockcroft Gault Equation) ≥ 60 mL/min Age (Years) Maximum Serum Creatinine (mg/dL)
  • 5 Years - Serum Creatinine (mg/dL) = 0.8; 5 < age ≤ 10 Years - Serum Creatinine (mg/dL) = 1.0; >10-18 years - Serum Creatinine (mg/dL) = 1.2; > 18 years - Serum Creatinine (mg/dL) = 2.0
  • Serum (alanine aminotransferase/aspartate aminotransferase(ALT/AST)≤ 10x upper limit of normal (ULN) (unless elevated ALT/AST is associated with leukemia involvement of the liver, in which case this criterion will be waived and not disqualify a patient).
  • Total bilirubin ≤ 1.5 mg/dl, except in subjects with Gilbert's syndrome.
  • Cardiac ejection fraction ≥ 45%, no evidence of physiologically significant pericardial effusion as determined by an ECHO,
  • No clinically significant ECG findings
  • No clinically significant pleural effusion
  • Baseline oxygen saturation > 92% on room air * if these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy); A subject will not be excluded because of pancytopenia ≥ Grade 3 if it is due to disease, based on the results of bone marrow studies.
  • CNS Status Subjects with CNS involvement are eligible as long as there are no overt signs or symptoms that in the evaluation of the investigator would mask or interfere with the neurological assessment of toxicity.
  • Pregnancy Test Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)
  • Contraception Subjects of child bearing or child fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) months after receiving the preparative regimen or for as long as CD19/CD22-CAR T cells are detectable in peripheral blood.
  • Ability to give informed consent. All subjects ≥ 18 years of age must be able to give informed consent. For subjects <18 years old their legal authorized representative (LAR) (i.e. parent or guardian) must give informed consent. Pediatric subjects will be included in age appropriate discussion and verbal assent will be obtained for those > 7 years of age, when appropriate. If a minor becomes of age during participation of this study, he/she will be asked to reconsent as an adult

Who cannot join

  • Recurrent or refractory ALL limited to isolated testicular disease.
  • Hyperleukocytosis (≥ 50,000 blasts/μL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy
  • History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years
  • Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management. Simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.
  • Ongoing infection with HIV or hepatitis B (HBsAg positive) or hepatitis C virus (anti HCV positive) as the immunosuppression contained in this study will pose unacceptable risk. A history of hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing.
  • CNS disorder such as cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement hat in the judgment of the investigator may impair the ability to evaluate neurotoxicity.
Show all 12Show fewer
  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.
  • Any medical condition that in the judgement of the sponsor investigator is likely to interfere with assessment of safety or efficacy of study treatment
  • History of severe immediate hypersensitivity reaction to any of the agents used in this study.
  • Women of child bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.
  • In the investigators judgment, the subject is unlikely to complete all protocol required study visits or procedures, including follow up visits, or comply with the study requirements for participation
  • Has primary immunodeficiency or history of autoimmune disease (e.g. Crohns, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Stanford Medical Center

    Stanford, California, 94304

Other trials in United States

About this study

Official title: Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

The primary purpose of this study is to test whether CD22-CAR T cells can be successfully made from immune cells collected from pediatric and young adult subjects with relapsed/refractory B-cell malignancies (leukemia and lymphoma). Another purpose of this study is to test the safety and cancer killing ability of a cell therapy against a new cancer target (CD22).

Read the detailed description

PRIMARY OBJECTIVE:

  • Determine the feasibility of manufacturing CD22 CAR T cells for administration to children and young adults with relapsed/refractory (R/R) CD22 expressing B-cell ALL or lymphoma using the Miltenyi CliniMACS Prodigy system.
  • Determine the safety of an established dose of CD22-CAR T cells in children and young adults with R/R CD22 expressing B-cell malignancies.

SECONDARY OBJECTIVE:

  • Assess the clinical activity of CD22-CAR T cells in children and young adults with R/R CD22 expressing B-cell malignancies, including overall survival (OS) and progression free survival (PFS).
Being tested
Fludarabine, Cyclophosphamide, Autologous CD22 CAR T
Medical subject headings
Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FludarabineDrug

    Fludarabine is a purine antagonist antimetabolite

  • CyclophosphamideDrug

    Cyclophosphamide is a nitrogen mustard derivative alkylating agent

  • Autologous CD22 CAR TDrug

    Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)

Study groups in NCT04088864
Study groupRoleWhat they receive
R/R B-ALLExperimentalSubjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0. Lymphodepletion: * Fludarabine 25 mg/m2 per day IV for days 4, 3, -2 * Cyclophosphamide 900 mg/m2 per day IV on day -2 Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10^6 transduced T cells/kg (± 20%)).
Receives: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Autologous CD22 CAR T
LymphomaExperimentalSubjects will receive a conditioning lymphodepletion chemotherapy regimen of fludarabine and cyclophosphamide followed by infusion of CD22 CAR T cells on Day0. Lymphodepletion: * Fludarabine 25 mg/m2 per day IV for days 4, 3, -2 * Cyclophosphamide 900 mg/m2 per day IV on day -2 Autologous CD22 CAR T cells will be administered intravenously at Dose level 1 (1 x 10^6 transduced T cells/kg (± 20%)).
Receives: Drug: Fludarabine; Drug: Cyclophosphamide; Drug: Autologous CD22 CAR T

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of successful manufacture of CD22 CAR T cells

    The percentage of apheresis samples (fresh or frozen) that are successfully processed and expanded to manufacture CD22 CAR T cells that satisfy the target dose level and meet release specifications will be determined for each disease group (ALL or lymphoma).

    Measured: 7-11 days after apheresis

  2. Safe dose of CD22-CAR T cells in subjects with R/R B-cell malignancies

    Incidence and severity of dose limiting toxicities (DLTs) following chemotherapy preparative regimen and infusion of CD22 CAR T cells, as recorded and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, at target dose of 1 x 10^6 transduced T cells/kg (± 20%).

    Measured: 28 days after infusion

Secondary outcomes (2)

  1. Clinical activity of CD22-CAR T cells in children and young adults with R/R CD22-expressing B-cell ALL and R/R lymphoma

    Clinical activity will be assessed by modified International Working Group response criteria for acute lymphoblastic leukemia (ALL). Results will be reported as best response (i.e. complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PR)) at Day 28 for adult subjects with ALL treated at the target dose.

    Measured: 28 days after infusion of CD22-CAR T cells

  2. Clinical activity of CD22-CAR T cells in adults with R/R lymphoma

    Clinical activity will be assessed by Lugano response criteria for lymphoma. Results will be reported as best response (i.e. complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PR)) at Month 3 for adult lymphoma/DLBCL subjects treated at Maximum tolerated dose (MTD) /recommended phase 2 dose (RP2D).

    Measured: 3 months after infusion of CD22-CAR T cells

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Sep 2019
  2. Study start10 Jan 2020
  3. Primary completion8 Nov 2021
  4. Study completion13 Jan 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04088864
Sponsor's protocol ID
IRB-50878
Other IDs
NCI-2019-07285
Status last verified
May 2026
First submitted
11 Sep 2019
Last updated
26 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Fludarabine, Cyclophosphamide and Autologous CD22 CAR T in people with B Cell Lymphoma and Acute Lymphoblastic Leukemia, Pediatric, run by Kara Lynn Davis at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 49 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of successful manufacture of CD22 CAR T cells (time frame: 7-11 days after apheresis). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04088864.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in